Effect of airway clearance therapies on mucociliary clearance in adults with cystic fibrosis: A randomized controlled trial

PLoS One. 2022 May 20;17(5):e0268622. doi: 10.1371/journal.pone.0268622. eCollection 2022.

Abstract

Background: Cystic fibrosis (CF) is an inherited disorder causing impaired mucociliary clearance within the respiratory tract, and is associated with bronchiectasis, chronic respiratory infections, and early death. Airway clearance therapies have long been a cornerstone of management of individuals with CF, although evidence supporting their use is lacking. We designed a randomized controlled trial to quantitatively compare the effects of different forms of airway clearance on mucociliary clearance.

Methods: Three different physiotherapy methods to augment cough-clearance were studied in addition to cough-clearance alone: high-frequency chest-wall oscillating vest, oscillatory positive expiratory pressure, and whole-body vibration. We used gamma scintigraphy after inhalation of radiolabeled particles to quantify mucus clearance before, during, and after physiotherapy. As secondary endpoints, we measured concentrations of small molecules in exhaled breath that may impact mucus clearance.

Results: Ten subjects were enrolled and completed study procedures. No differences were identified between any method of airway clearance, including cough clearance alone. We did identify changes in certain small molecule concentrations in exhaled breath following airway clearance.

Conclusions: Due to the limitations of this study, we do not believe the negative results suggest a change in clinical practice with regard to airway clearance. Findings pertaining to small molecules in exhaled breath may serve as future opportunities for study.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cough / complications
  • Cystic Fibrosis* / complications
  • Forced Expiratory Volume
  • Humans
  • Mucociliary Clearance*
  • Mucus

Grants and funding

This work was supported by a grant to AT and SD from the Cystic Fibrosis Foundation (http://www.cff.org REACT16A0). The funders of this study were not involved in the study design, execution of the procedures, data analysis, preparation of the manuscript, or decision to publish. Investigators received no financial support from commercial entities for the completion of this study. A PowerPlate® device was provided by the manufacturer, Performance Health Systems LLC, Northbrook, IL, USA.